Soligenix to Present at 8th Annual BIO Inve...(bioterror threats manufacturing and cond...)

Date:10/27/2009

bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for gastrointestinal GVHD include the risks that: the FDA's requirement that Soligenix conduct additional clinical trials to demonstrate the safety and efficacy of orBec® will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; Soligenix is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec® may not gain market acceptance if it is eventually approved by the FDA; and others may develop technologies or products superior to orBec®. Factors affecting the development and use of SGX201 and LPM(TM) are similar to those affecting orBec®. These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix's mo
'/>"/>

SOURCE Soligenix, Inc. Copyright©2009 PR Newswire. All rights reserved

3 GOOD

Page: 1 2 3 4
Related biology technology :

1. Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
2. DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX
3. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009
4. Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDFs 20th World Diabetes Congress
5. Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31, 2009
6. Transdel Pharmaceuticals to Present at Two Investor Conferences
7. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 2009 BIOCOM INVESTOR CONFERENCE
8. Advanced Life Sciences to Present at 8th Annual BIO Investor Forum
9. Researchers Present a Novel, Automated, Efficient Environmental Disinfection Technology that Significantly Reduces C. difficile, VRE and MRSA Contamination
10. China Pharma Holdings, Inc. to Present at the Roth China Conference on October 14 at 12:00 pm ET
11. 17th International Process Development Conference to Feature Presentations on Safety, Process Development, Crystallization, PAT, Scale-Up and Production